

Meet 2-times-a-year* OCREVUS ZUNOVO® and OCREVUS® [IV]

*For OCREVUS [IV], your first dose will be split into 2, for a total of 3 treatments your first year.

LEANN

Using
OCREVUS ZUNOVO



What are OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?

Do not receive OCREVUS or OCREVUS ZUNOVO if you:

- have an active hepatitis B virus (HBV) infection.
- have had a life-threatening administration reaction to ocrelizumab.
- have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Infusion reactions (OCREVUS):** Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
- **Injection reactions (OCREVUS ZUNOVO):** Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.

Please see additional important safety information throughout and click for OCREVUS prescribing information and medication guide, and OCREVUS ZUNOVO prescribing information and medication guide.

OCREVUS ZUNOVO®
ocrelizumab hyaluronidase
injection (aqueous suspension)



OCREVUS®
ocrelizumab



You have options when it comes to MS treatments

Find out which OCREVUS option may be right for you.

- 4 Results in Relapsing MS (RMS)
- 11 Results in Primary Progressive MS (PPMS)
- 14 How OCREVUS ZUNOVO and OCREVUS Are Given
- 18 Important Safety Information
- 20 Infusion and Injection Reactions
- 21 How OCREVUS ZUNOVO and OCREVUS May Work
- 22 FAQs
- 24 MS in Black and Hispanic People
- 26 OCREVUS CONNECTS[®] and Financial Support
- 28 Talking to Your Doctor

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).



2-TIMES-A-YEAR* OCREVUS is AVAILABLE 2 WAYS for treating RMS and PPMS

~10-minute[†]
subcutaneous injection

OCREVUS ZUNOVO[™]
ocrelizumab-hyaluronidase-ecq
Subcutaneous injection 100mg/20,000 units



4-hour[†]/2-hour^{}**
intravenous infusion

OCREVUS[®]
ocrelizumab-iv



The duration of an infusion or injection could be longer should a reaction occur.

**Talk to your doctor about starting or switching to
OCREVUS ZUNOVO or OCREVUS**

*For OCREVUS (IV), your first dose will be split into 2, for a total of 3 treatments your first year.

**This is only administration time and does not account for all aspects of treatment. Actual clinic time may vary.

†For eligible patients who have not previously experienced any serious infusion reactions with OCREVUS.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

• Infection:

• Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO[™]
ocrelizumab-hyaluronidase-ecq
Subcutaneous injection 100mg/20,000 units



OCREVUS[®]
ocrelizumab-iv



OCREVUS ZUNOVO® and OCREVUS® [IV] have been proven to reduce relapses, slow disability progression, and reduce brain lesions

OCREVUS [IV] was proven in 2 studies against Rebif®

In 2 large, identical clinical studies over 2 years, OCREVUS was proven effective against Rebif®, a currently approved treatment for relapsing MS, not a placebo. A placebo is a substance or treatment that has no active medicine.

OCREVUS [IV] was studied in 1600+ people with active MS

1656 people, 18-55 years old, with a 4-year average since diagnosis (827 received OCREVUS, 829 received Rebif®)

Had experienced ≥ 2 relapses in last 2 years or ≥ 1 relapse in last year

Had T1 gadolinium-enhancing (Gd+) lesions and/or T2 hyperintense lesions

*Rebif® is a registered trademark of UCB Sonoma, Inc.

The similarity of OCREVUS ZUNOVO subcutaneous injections to OCREVUS infusions was confirmed in a separate study

This study measured the amount of medicine in the bloodstream, which is commonly done to check that the injection works like the infusion. The results of the study showed there were no clinically significant differences between OCREVUS and OCREVUS ZUNOVO.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Hepatitis B virus (HBV) reactivation:** If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
sponsored by Genentech
a member of the Roche Group



OCREVUS®
sponsored by Genentech
a member of the Roche Group



LEIKA
Using
OCREVUS ZUNOVO



It's good to talk about MS.
The people you care about
and who care about you
should know what it's like.

TAKE A LOOK AT STORIES FROM
REAL PEOPLE LIVING WITH MS

Explore Now

OCREVUS® reduced relapses

OCREVUS cut relapses nearly in half.

OCREVUS reduced relapses by

46%

compared with
Rebif in Study 1

More people taking OCREVUS had no relapses.



83%

of people taking
OCREVUS had no relapses

compared with **71%** for Rebif in Study 1

Results were consistent in Study 2.

OCREVUS ZUNOVO® has been built on 10+ years of OCREVUS [IV] experience and results

Experience matters when choosing how to treat your MS.

OCREVUS [IV] was proven effective against Rebif in an initial 2-year study. At the end of the initial 2-year period, patients could either continue with OCREVUS or switch to OCREVUS from Rebif and continue to be observed for an additional 8+ years. The OCREVUS study examined patients over 10+ years. To find out more about the results of this study, talk to your doctor.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Vaccinations:** Tell your doctor about any recent or upcoming vaccinations.
 - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.
 - When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
and Rebif by Genentech
are trademarks of Genentech.



OCREVUS®
and Rebif® by Genentech



EMILY
Using OCREVUS

“
My neuro told me what I do today can affect my tomorrow. I choose OCREVUS for my now and for my future.”

OCREVUS® slowed disability progression in relapsing MS

People taking OCREVUS were

40% LESS LIKELY

to have disability progression than those taking Rebif®

9.8% of people taking OCREVUS had disability progression

compared with

15.2% of people taking Rebif



What is disability progression?

Disability progression is the increase in physical disability that happens over time for people with MS. How and when it happens is different for everyone.

Rebif is a registered trademark of EMMES, Inc.

Disability progression was confirmed 3 months after the initial neurological change and confirmed again after 6 months.

OCREVUS was proven to reduce brain lesions on MRI



In Study 1, there were

94%

Fewer T1 Gadolinium-enhancing lesions (GD+)* compared to Rebif

Results were consistent in Study 2.

The average number of T1 Gd+ lesions per MRI was lower for OCREVUS:

Study 1: **0.016** lesions with OCREVUS compared with **0.286** lesions with Rebif

Study 2: **0.021** lesions with OCREVUS compared with **0.416** lesions with Rebif

For more information, please visit OCREVUS.com

*T1 gadolinium-enhancing (Gd+) lesion is a magnetic resonance imaging (MRI) indicator that highlights active inflammation that has occurred. Active inflammation means that myelin is being damaged or destroyed. T1 Gd+ lesions are thought to be a sign of active inflammation.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Weakened immune system:** OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
- **Progressive Multifocal Leukoencephalopathy (PML):** PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks.
- **Decreased immunoglobulins:** OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:

- **Risk of cancers (malignancies) including breast cancer:** Follow your healthcare provider's instructions about standard screening guidelines for breast cancer.
- **Inflammation of the colon, or colitis:** Tell your healthcare provider if you have any symptoms of colitis, such as diarrhea, blood in stool, and stomach pain.
- **Liver damage:** OCREVUS and OCREVUS ZUNOVO may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start OCREVUS or OCREVUS ZUNOVO and while you take OCREVUS or OCREVUS ZUNOVO if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as: yellowing of the skin and eyes (jaundice), nausea, vomiting, unusual darkening of the urine, feeling tired or weak.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:

- **The most common side effects of OCREVUS ZUNOVO include:** injection reactions, respiratory tract infections, and skin infections. These are not all the possible side effects of OCREVUS and OCREVUS ZUNOVO.

These are not all the possible side effects of OCREVUS and OCREVUS ZUNOVO.

What are OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?

Do not receive OCREVUS or OCREVUS ZUNOVO if you:

- have an active hepatitis B virus (HBV) infection.
- have had a life-threatening administration reaction to ocrelizumab.
- have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.

Please see additional important safety information throughout and click for OCREVUS [prescription information](#) and [medication guide](#), and OCREVUS ZUNOVO [prescription information](#) and [medication guide](#).

OCREVUS ZUNOVO
only available by prescription
from a healthcare provider



OCREVUS®
only available by prescription
from a healthcare provider



Please see additional important safety information throughout and click for OCREVUS [prescription information](#) and [medication guide](#), and OCREVUS ZUNOVO [prescription information](#) and [medication guide](#).

OCREVUS ZUNOVO
only available by prescription
from a healthcare provider



OCREVUS®
only available by prescription
from a healthcare provider



IZZY

Using OCREVUS

“

There aren't any other approved treatments for **PPMS**, so it was good news when my doctor told me about OCREVUS.

RESULTS IN PRIMARY PROGRESSIVE MS (PPMS)

OCREVUS ZUNOVO® and OCREVUS® [IV] have been proven to slow disability progression and reduce brain lesions

OCREVUS treatment options are the only ones approved to treat PPMS. OCREVUS [IV] was proven in a clinical study, compared to placebo. Patients were treated for at least 120 weeks.

Here are the people included in the studies

732 people
(488 received OCREVUS, 244 received placebo)

18-55 years of age

Average time since people experienced the start of symptoms was about 7 years

88% had not previously received MS disease-modifying treatment
versus 12% who had

Why this is important

Studied in a large number of people

Studied in a variety of people who have MS

Study included people who had not been taking a treatment and those who had

The similarity of OCREVUS ZUNOVO subcutaneous injections to OCREVUS infusions was confirmed in a separate study

This study measured the amount of medicine in the bloodstream, which is commonly done to check that the injection works like the infusion. The results of the study showed there were no clinically significant differences between OCREVUS and OCREVUS ZUNOVO.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Infusion reactions (OCREVUS):** Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.

Please see additional important safety information throughout and click for OCREVUS [prescribing information](#) and [medication guide](#), and OCREVUS ZUNOVO [prescribing information](#) and [medication guide](#).

OCREVUS ZUNOVO
subcutaneous injections
[learnmoreaboutocrevus.com](#)



OCREVUS®
innovative
[learnmoreaboutocrevus.com](#)

OCREVUS[®] is proven to slow disability progression and reduce brain lesions in PPMS

People taking OCREVUS were



**24%
LESS LIKELY**

to have disability progression than those taking placebo^a

32.9% of people taking OCREVUS had disability progression

compared with

39.3% of people taking placebo^a

OCREVUS saw superior results in brain lesion volume

OCREVUS saw a



**3%
REDUCTION**

in T2 lesion volume^a

Placebo saw a



**7%
INCREASE**

in T2 lesion volume^a

OCREVUS [n] reduced the volume of T2 hyperintense lesions, while T2 lesion volume increased in people taking placebo. The average change in volume of T2 lesions was -0.29 cm³ for OCREVUS [n] compared with 0.29 cm³ for placebo.^a

^aDisability progression was confirmed 2 months after the initial neurological change.

^bDisability progression was also confirmed after 6 months.

^cOCREVUS was evaluated in a study including 132 people who were treated with OCREVUS or placebo for at least 120 weeks.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Injection reactions (OCREVUS ZUNOVO):** Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
sponsored by Genentech
a member of the Roche Group



OCREVUS[®]
sponsored by
Genentech



IZZY
Using OCREVUS

“

MS has slowed me down a little, but it's hardly taken the fight out of me for good.

2 types of administration

TREATMENT TYPE	 OCREVUS ZUNOVO	 OCREVUS
Approved for:	Adults with RMS and PWS	
Doses per year:	<p>2 doses per year One 600 mg dose injected every 6 months</p> <p>First dose is not split</p>	<p>2 doses per year The first dose is split into two 300 mg infusions 2 weeks apart</p> <p>Further doses are administered as one 600 mg infusion every 6 months</p>
Treatment administration:	A subcutaneous injection under the skin, in your abdomen area	An intravenous infusion into a vein in your arm
Treatment administration time ¹ :	Approximately 10 minutes	Approximately 4 hours or 2 hours
<small>*Administration time could be longer should you experience an adverse event.</small>		Depending on how you respond to the first dose or subsequent doses, your doctor may recommend the shorter infusion option
Given by:	A healthcare professional	

See page 11 for more information on the treatment experience, including premedication and post-dose observation requirements for OCREVUS and OCREVUS ZUNOVO.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

• **Infection:**

- Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.

Please see additional Important Safety Information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
sponsored by Amgen and
Novartis



OCREVUS[®]
sponsored by Amgen and
Novartis



LEANN
Using
OCREVUS ZUNOVO

“
Every day is different, so I've learned to listen to my body and check in to see what I can accomplish.”

WANDA
Using
OCREVUS ZUNOVO



Everybody with MS has a different story, but one thing's the same — it's better to start treatment as soon as you can.

What happens at an OCREVUS appointment?

TREATMENT TYPE	OCREVUS ZUNOVO	OCREVUS
Treatment location	After talking to your doctor, you may be able to receive it at their office, a treatment center, or at home from a home health provider	
Premedication	You will take premedication at least 30 minutes before starting each OCREVUS ZUNOVO treatment, usually as pills to swallow. You may be able to take your medications at home. Your healthcare team will advise on all pretreatment protocols	You will be given premedication 30-60 minutes before starting your OCREVUS treatment, usually as part of your IV infusion
Administration time (see page 14)	~10 minutes	The IV itself will take between 2-4 hours based upon the administration option selected by your HCP
Treatment overview	<p>You will be asked to sit or lie down, and a thin needle will be inserted under the skin in your abdomen area. This needle will be connected to the prepared syringe containing OCREVUS ZUNOVO</p> <p>A member of your healthcare team will either inject OCREVUS ZUNOVO manually or will use an automatic pump</p>	<p>A thin needle will be inserted into your arm to start the infusion of OCREVUS. An automatic pump will also be set up to ensure you receive the exact amount</p> <p>Depending on how you respond to the first dose or subsequent doses of OCREVUS, your doctor may recommend a shorter or longer infusion time</p>
Monitoring after treatment	<p>Your healthcare team will observe you for at least one hour after your first injection</p> <p>For every injection after that, you will be observed for at least 15 minutes</p>	Your healthcare team will observe you for at least an hour after your infusion

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO? OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Hepatitis B virus (HBV) reactivation:** If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death.

Please see additional Important Safety Information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
solumbra therapies



OCREVUS®
solumbra therapies

Important Safety Information

What are OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
 - Primary progressive MS, in adults
- It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

Who should not receive OCREVUS or OCREVUS ZUNOVO?

Do not receive OCREVUS or OCREVUS ZUNOVO if you:

- have an active hepatitis B virus (HBV) infection.
- have had a life-threatening administration reaction to ocrelizumab.
- have had a life-threatening allergic reaction to ocrelizumab, hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Infection reactions (OCREVUS):** Infection reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infection reaction.
- **Injection reactions (OCREVUS ZUNOVO):** Injection reactions are a common side effect of OCREVUS ZUNOVO, which can be serious and may require you to be hospitalized. You will be monitored for signs and symptoms of an injection reaction when you receive OCREVUS ZUNOVO. This will happen during all injections for at least 1 hour after your first injection, and for at least 15 minutes after all injections following the first injection.

Tell your healthcare provider or nurse if you get any of these symptoms:

- | | |
|-----------------------------------|--------------------------|
| - Itchy skin | - nausea |
| - rash | - headache |
| - blives | - swelling of the throat |
| - tiredness | - dizziness |
| - coughing or wheezing | - shortness of breath |
| - trouble breathing | - fatigue |
| - throat irritation or pain | - fast heartbeat |
| - feeling faint | - fever |
| - redness on your face (flushing) | |

Please see additional important safety information throughout and click for OCREVUS [prescribing information](#) and [medication guide](#), and OCREVUS ZUNOVO [prescribing information](#) and [medication guide](#).

Additionally, for OCREVUS ZUNOVO:

- injection site pain
- swelling
- redness

These infusion and injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion or injection.

- Infection:

- Infections are a common side effect. OCREVUS and OCREVUS ZUNOVO increase your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS and OCREVUS ZUNOVO, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS or OCREVUS ZUNOVO. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS or OCREVUS ZUNOVO until your infection is gone.

- **Hepatitis B virus (HBV) reactivation:** Before starting treatment with ocrelizumab, your healthcare provider will do blood tests to check for hepatitis B virus infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death.

Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS or OCREVUS ZUNOVO.

- **Weakened immune system:** OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

- Progressive Multifocal Leukoencephalopathy (PML):

PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:

- | | |
|------------|-----------------------------------|
| - thinking | - balance |
| - eyesight | - weakness on 1 side of your body |
| - strength | - using your arms or legs |

- **Decreased immunoglobulin:** OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving OCREVUS or OCREVUS ZUNOVO, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection. See "What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?"
- have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. These medicines could increase your risk of getting an infection.
- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have a history of inflammatory bowel disease or colitis.
- have a history of liver problems.
- have had a recent vaccination or are scheduled to receive any vaccination.
- **You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with OCREVUS or OCREVUS ZUNOVO and until your healthcare provider tells you that your immune system is no longer weakened.**

- **When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.** If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS or OCREVUS ZUNOVO, talk to your healthcare provider.

- **If you have a baby and you received OCREVUS or OCREVUS ZUNOVO during your pregnancy, it is important to tell your baby's healthcare provider about receiving OCREVUS or OCREVUS ZUNOVO so they can decide when your baby should be vaccinated.**

- **are pregnant, think that you might be pregnant, or plan to become pregnant.** It is not known if OCREVUS and OCREVUS ZUNOVO will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and OCREVUS ZUNOVO and for 6 months after your last dose of OCREVUS or OCREVUS ZUNOVO. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving OCREVUS or OCREVUS ZUNOVO.

- **are breastfeeding or plan to breastfeed.** It is not known if OCREVUS and OCREVUS ZUNOVO pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS or OCREVUS ZUNOVO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:

- **Risk of cancer (malignancies) including breast cancer:** Follow your healthcare provider's instructions about standard screening guidelines for breast cancer.
- **Inflammation of the colon, or colitis:** Tell your healthcare provider if you have any symptoms of colitis, such as:
 - Diarrhea (loose stools) or more frequent bowel movements than usual
 - Stools that are black, tarry, sticky or have blood or mucus
- **Severe stomach-area (abdomen) pain or tenderness**
- **Liver damage:** OCREVUS and OCREVUS ZUNOVO may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start OCREVUS or OCREVUS ZUNOVO and while you take OCREVUS or OCREVUS ZUNOVO if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as:
 - yellowing of the skin and eyes (jaundice)
 - nausea
 - vomiting
 - unusual darkening of the urine
 - feeling tired or weak

The most common side effects of OCREVUS ZUNOVO include:

- Injection reactions
- Respiratory tract infections
- Skin infections

These are not all the possible side effects of OCREVUS and OCREVUS ZUNOVO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (866) 835-2555.

For more information, go to www.OCREVUS.com or call 1-866-627-3887.

Please see additional important Safety information throughout and click here for full [prescribing information](#) and [Medication Guide for OCREVUS](#).

Please see additional important Safety information throughout and click here for full [prescribing information](#) and [Medication Guide for OCREVUS ZUNOVO](#).

Infusion and injection reactions

Infusion and injection reactions are a common side effect of OCREVUS[®] [IV] and OCREVUS ZUNOVO[®], and can be serious and require you to be hospitalized. You will be monitored during your treatment for signs and symptoms of a reaction. Reactions are most common during and within an hour after treatment but can occur up to 24 hours afterward.

Please tell your healthcare provider or nurse if you get any of these symptoms:

- | | | |
|------------------------|-----------------------------------|--------------------------|
| • itchy skin | • throat irritation or pain | • swelling of the throat |
| • rash | • feeling faint | • dizziness |
| • hives | • fever | • shortness of breath |
| • tiredness | • redness on your face (flushing) | • fatigue |
| • coughing or wheezing | • nausea | • fast heartbeat |
| • trouble breathing | • headache | |

Additionally, for OCREVUS ZUNOVO: injection site pain, swelling, or redness.

In a clinical study, injection reactions were more frequently reported with the first injection. All reactions were mild to moderate and treatable with treatment adjustments and medicines to help with reactions.

An increased risk of malignancies may exist

An increased risk of malignancies, including breast cancer, may exist with OCREVUS. Follow your healthcare provider's instructions about standard screening guidelines for breast cancer.

In 3 main clinical trials, 6* of 781 females (<1%) receiving OCREVUS were diagnosed with breast cancer. There were no cases of breast cancer during the trial period among patients taking Rebif or placebo.

*relapsing MS and 4 PPMS patients.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Vaccinations:** Tell your doctor about any recent or upcoming vaccinations.
 - You should receive any required "live" or "live-attenuated" vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.
 - When possible, you should receive any "non-live" vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.
- **Weakened immune system:** OCREVUS or OCREVUS ZUNOVO taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

LEIKA

Using
OCREVUS ZUNOVO

HOW OCREVUS ZUNOVO AND OCREVUS MAY WORK

MS is thought to affect both the central nervous system and the immune system

In the body:

- The **central nervous system** (the brain and spinal cord) carries signals to and from the rest of the body via nerve cells. These signals allow us to move, see, and sense things.
- The **immune system** uses many types of cells, including B cells and T cells, to help the body fight infections caused by viruses or bacteria.

In people with MS, instead of fighting infections, some B cells and T cells are misdirected to attack myelin (the fatty sheath that protects nerves and helps maintain the signals carried by the nerves).

While it is not exactly known how OCREVUS works, it is thought to target certain types of B cells, which scientists agree play an important role in the process of MS.

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- **Progressive Multifocal Leukoencephalopathy (PML):** PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks.
- **Decreased immunoglobulins:** OCREVUS and OCREVUS ZUNOVO may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
and ocrelizumab
solutions for intravenous
use

OCREVUS[®]
and ocrelizumab

FAQs

Q. Are OCREVUS and OCREVUS ZUNOVO well-established treatments for MS?

A. OCREVUS (IV) is a well-established medicine. More than 450,000 people with MS have been treated globally with OCREVUS since its approval in 2017. OCREVUS ZUNOVO was approved in 2024.

Q. What is a subcutaneous injection?

A. A subcutaneous (SC, SQ, or Sub-Q) injection is given to the fatty tissue under the skin. OCREVUS ZUNOVO is a subcutaneous injection.

Q. Can I switch from OCREVUS to OCREVUS ZUNOVO?

A. While all treatment decisions should be discussed and made with your healthcare team, some patients did switch from OCREVUS to OCREVUS ZUNOVO in the OCARINA II clinical trial. Talk to your doctor about this clinical trial data and whether switching from OCREVUS to OCREVUS ZUNOVO may be right for you.

Q. Why does OCREVUS offer so many treatment options? How do I know which one is right for me?

A. Every person living with MS is different, and that is why choice is essential. Choosing a treatment plan is a joint decision between you and your doctor. Talk to your doctor about which OCREVUS treatment option is most appropriate for you.

Q. Why are there different active doses of OCREVUS ZUNOVO and OCREVUS?

A. The administration of OCREVUS ZUNOVO is a single 920 mg injection under the skin of the abdomen. This dose is higher than the 600 mg OCREVUS intravenous dose because of the different routes to the bloodstream.

With subcutaneous medications: The drug is administered into the subcutaneous tissue, which may impact the amount of medicine and/or the time it takes for the medicine to reach the bloodstream.

With intravenous medications: The drug is directly administered into the vein, so these medications directly reach the blood circulation.

Therefore, a higher dose of OCREVUS ZUNOVO is needed to achieve a similar medical effect to OCREVUS.

Q. What is hyaluronidase?

A. OCREVUS ZUNOVO contains an additional ingredient, an enzyme called recombinant human hyaluronidase. It helps OCREVUS ZUNOVO to be absorbed into the body when it is injected under the skin.

LEANN
Using
OCREVUS ZUNOVO

“
MS is a lot to adjust to at first, but that's the thing. You can adjust to it.”



MS in Black and Hispanic People

MS was once thought to be a disease that primarily affects White people. However, more Black and Hispanic people have MS than previously thought.

Black and Hispanic people may also be at greater risk of disability progression, so it's important to seek care right away and follow your treatment plan.

Our Commitment to Supporting All People With MS

Because Black and Hispanic people continue to be underrepresented in clinical trials, there's limited data on what drives disability progression in these populations. That's why at Genentech, we created the first-ever clinical trial* focused exclusively on how MS impacts Black and Hispanic people.

*OCREUS Study: Characterization of Disability in Minorities with Multiple Sclerosis

At Genentech, we are committed to helping all MS patients live longer, healthier lives. Initiatives we are taking include:



Focusing on the equity of all MS patients in the design of our clinical studies



Expanding our ability to treat all MS patients, especially those facing the greatest barriers to care



Working with our partners to optimize outcomes for all MS patients

Important Safety Information for OCREVUS and OCREVUS ZUNOVO (cont.)

What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?
OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:

- **Risk of cancers (malignancies) including breast cancer:** Follow your healthcare provider's instructions about standard screening guidelines for breast cancer.
- **Inflammation of the colon, or colitis:** Tell your healthcare provider if you have any symptoms of colitis, such as diarrhea, blood in stool, and stomach pain.
- **Liver damage:** OCREVUS and OCREVUS ZUNOVO may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start OCREVUS or OCREVUS ZUNOVO and while you take OCREVUS or OCREVUS ZUNOVO if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as: yellowing of the skin and eyes (jaundice), nausea, vomiting, unusual darkening of the urine, and feeling tired or weak.
- **The most common side effects of OCREVUS ZUNOVO include:** injection reactions, respiratory tract infections, and skin infections.

These are not all the possible side effects of OCREVUS and OCREVUS ZUNOVO.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
confidentially sponsored by
Genentech and Biogen



OCREVUS[®]
confidentially sponsored by
Genentech and Biogen



ALEX
Using OCREVUS

CHANTAL
Using OCREVUS

LEARN ABOUT THE BLACK MS EXPERIENCE

Go Now

LEANN
Using
OCREVUS ZUNOVO

WANDA
Using
OCREVUS ZUNOVO

Support and guidance for when you need it



Call 1-844-OCREVUS to speak directly with someone who can answer your questions about OCREVUS treatment options and MS and provide information about financial assistance programs that may be available to you.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

Here to help you on your treatment journey

Once you have been prescribed OCREVUS ZUNOVO* or OCREVUS[®] [IV], you can choose to enroll in a free program where you may be teamed up with either a Patient Navigator or a Clinical Education Manager (CEM) or both.

HOW A PATIENT NAVIGATOR CAN SUPPORT YOU



Coordinating finding a treatment location



Helping you understand insurance coverage for your treatment



Identifying financial assistance options, if you're eligible

HOW A CLINICAL EDUCATION MANAGER* CAN SUPPORT YOU

1:1

Offering one-on-one education sessions about OCREVUS ZUNOVO, OCREVUS, and MS



Helping you prepare for your first treatment by explaining what to expect



Detailing local MS resources that may be available

Visit [OCREVUS.com/connects](https://ocrevus.com/connects) to see all the ways this service can offer help.

OCREVUS CONNECTS[®] is available Monday-Friday, 9 AM to 8 PM ET. If you have questions about your specific medical condition or care, be sure to talk to your doctor.

FINANCIAL ASSISTANCE

We want you to have access to the OCREVUS treatment option you are prescribed

We understand that cost can be one of the biggest barriers to treatment. That's why we're committed to helping you. Here are some of the resources we offer to help you in regard to cost.

The OCREVUS Co-pay Program

Independent Co-pay Assistance Foundations

Genentech Patient Foundation

Visit [OCREVUS.com/access](https://ocrevus.com/access) to learn how these programs may help eligible patients pay for treatment.

The OCREVUS Co-pay Program: Eligibility criteria apply that vary for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.

Independent Co-pay Assistance Foundations: Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. Genentech does not endorse or show preference for any particular foundation. The foundations are able to help you may not be the only ones that might be able to help you.

Genentech Patient Foundation: If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover your Genentech medicine, you must meet a different set of income requirements. Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

Please see additional important safety information throughout and click for OCREVUS [Prescribing Information](#) and [Medication Guide](#), and OCREVUS ZUNOVO [Prescribing Information](#) and [Medication Guide](#).

OCREVUS ZUNOVO
and its associated trademarks
are trademarks of Genentech, Inc.



OCREVUS[®]
and its associated trademarks
are trademarks of Genentech, Inc.

It's your move. ☺
Talk to your doctor
about 2-times-a-year*
OCREVUS ZUNOVO®
and OCREVUS® [IV]

*For OCREVUS [IV], your first dose will be split into 3, for a total of 3 treatments your first year.

LEIKA

Using
OCREVUS ZUNOVO

To help start the conversation, get our Doctor Discussion Guide.
It's a list of questions to ask so you're fully prepared to talk with your doctor.
Access it at [OCREVUS.com/DDG](https://www.ocrevus.com/DDG).

Learn More

about OCREVUS ZUNOVO
and OCREVUS at [OCREVUS.com](https://www.ocrevus.com)

Click Here

to watch the OCREVUS ZUNOVO
administration video

Please see additional important safety information
throughout and click for OCREVUS [prescribing information](#)
and [administration guide](#), and OCREVUS ZUNOVO [prescribing](#)
[information](#) and [administration guide](#).

©2020 Genentech USA, Inc. All rights reserved. H-01-00003000(v10.0) H/20

OCREVUS ZUNOVO®
and Lunas tyrosine-kinase
inhibitors (TKIs) are registered trademarks of Genentech.



OCREVUS®
ocrevus.com

